These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 31389628)

  • 1. Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype.
    Shenderov E; Isaacsson Velho P; Awan AH; Wang H; Mirkheshti N; Lotan TL; Carducci MA; Pardoll DM; Eisenberger MA; Antonarakis ES
    Prostate; 2019 Sep; 79(13):1572-1579. PubMed ID: 31389628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).
    Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
    Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC).
    Custodio-Cabello S; Pacheco-Barcia V; Palka-Kotlowska M; Fernández-Hernández L; Del Álamo JF; Oliveros-Acebes E; Cabezón-Gutiérrez L
    Urol Oncol; 2024 Oct; 42(10):331.e13-331.e24. PubMed ID: 38926076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world retrospective study of prostate-specific antigen and safety assessment with darolutamide plus androgen deprivation therapy for metastasis hormone-sensitive prostate cancer.
    Liu J; Wang S; Yang Y; Wang S; Campobasso D; Tan YG; Gao Q; Yang L; Cao Y; Ji Y; Du P; Zhang B
    Transl Androl Urol; 2024 Mar; 13(3):433-441. PubMed ID: 38590967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.
    Markowski MC; Sternberg CN; Wang H; Wang T; Linville L; Marshall CH; Sullivan R; King S; Lotan TL; Antonarakis ES
    Oncologist; 2024 Sep; 29(9):794-800. PubMed ID: 38885246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer.
    Fang S; Zhe S; Lin HM; Azad AA; Fettke H; Kwan EM; Horvath L; Mak B; Zheng T; Du P; Jia S; Kirby RM; Kohli M
    JCO Clin Cancer Inform; 2023 Jul; 7():e2300057. PubMed ID: 37490642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report and literature review of rezvilutamide in the treatment of hormone-sensitive prostate cancer.
    Zhang C; Ren J; Kang Y; Chang D
    Front Oncol; 2024; 14():1374039. PubMed ID: 38577344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.
    Thysell E; Köhn L; Semenas J; Järemo H; Freyhult E; Lundholm M; Thellenberg Karlsson C; Damber JE; Widmark A; Crnalic S; Josefsson A; Welén K; Nilsson RJA; Bergh A; Wikström P
    Mol Oncol; 2022 Feb; 16(4):846-859. PubMed ID: 34889043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages.
    Potluri HK; Ng TL; Newton MA; Zhang J; Maher CA; Nelson PS; McNeel DG
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33335027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic Tumor Testing in Prostate Cancer: Experience of a Tertiary Care Center Including Pathologist-Driven Reflex Testing of Localized Tumors at Diagnosis.
    Prendeville S; Kaur H; Ansari S; Al Qa'qa' S; Stockley TL; Lajkosz K; van der Kwast T; Cheung CC; Selvarajah S
    Mod Pathol; 2024 Jun; 37(6):100489. PubMed ID: 38588883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
    Gilson C; Ingleby F; Gilbert DC; Parry MA; Atako NB; Ali A; Hoyle A; Clarke NW; Gannon M; Wanstall C; Brawley C; Mason MD; Malik Z; Simmons A; Loehr A; Parry-Jones A; Eeles R; Kote-Jarai Z; James ND; Amos C; Parmar MKB; Langley RE; Sydes MR; Attard G; Chowdhury S;
    JCO Precis Oncol; 2020 Nov; 4():882-897. PubMed ID: 35050761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer patient stratification by molecular signatures in the Veterans Precision Oncology Data Commons.
    Hernandez KM; Venkat A; Elbers DC; Bihn JR; Brophy MT; Do NV; La J; Liu Q; Prokhorenkov A; Metoki-Shlubsky N; Sung FC; Paller CJ; Fillmore NR; Grossman RL
    Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38050021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases.
    Shui IM; Burcu M; Shao C; Chen C; Liao CY; Jiang S; Cristescu R; Parikh RB
    Prostate Cancer Prostatic Dis; 2023 Dec; ():. PubMed ID: 38057611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-omics analysis reveals the
    Hsiao TH; Chiu YC; Shao YJ
    Transl Cancer Res; 2019 Aug; 8(4):1279-1288. PubMed ID: 35116870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications.
    Ryan MJ; Bose R
    Front Oncol; 2019; 9():1287. PubMed ID: 31824860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of evolutionary dynamics and clonal architecture in prostate cancer.
    Conway JR; Tewari AK; Camp SY; Han S; Crowdis J; He MX; Nyame YA; AlDubayan SH; Schultz N; Szallasi Z; Pomerantz MM; Freedman ML; Fong L; Nelson PS; Brown M; Salari K; Allen EV
    bioRxiv; 2023 Mar; ():. PubMed ID: 36993558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic Prostate Cancer With Reticular Micronodular Opacities of Lung: A Case Report.
    Bojja S; Javed N; Aziz MA; Fortuzi K; Khaja M
    Cureus; 2023 Jul; 15(7):e42698. PubMed ID: 37654947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary metastases from prostate cancer.
    Fabozzi SJ; Schellhammer PF; el-Mahdi AM
    Cancer; 1995 Jun; 75(11):2706-9. PubMed ID: 7743474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.
    Maekawa S; Takata R; Obara W
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological and molecular analysis of microsatellite instability in prostate cancer: a multi-institutional study in China.
    Zhang H; Yang X; Xie J; Cheng X; Chen J; Shen M; Ding W; Wang S; Zhang Z; Wang C; Zhao M
    Front Oncol; 2023; 13():1277233. PubMed ID: 37901334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.